Degron Therapeutics
Global leader in molecular glue degrader medicines
San Diego, United States · Founded 2021 · $62.0M raised
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2021
- Business Model
- B2B
- Website
- degronsci.com
- Total Funding
- $62.0M
- Last Round
- $40.0M Extension RoundMay 2026
- Rounds
- 2
About
Degron Therapeutics is a clinical-stage biotech developing molecular glue degrader drugs targeting previously undruggable proteins in oncology, inflammation, and metabolic disease. Founded in 2021, the company has advanced its lead asset DEG6498, a first-in-class HuR-targeting MGD, into Phase 1 clinical trials. Headquartered in San Diego with operations in Shanghai.
Summary
Degron Therapeutics is a Biotech company based in San Diego, United States, founded in 2021. It has raised $62.0M in total across 2 rounds, most recently a $40.0M Extension Round in May 2026. Investors include Lapam Capital, Med-Fine Capital and DYEE Capital.
Funding History
May 2026
Sign up to see all 2 events
Funding: Series A through Extension Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/degron-therapeutics"><img src="https://indexed.vc/api/badge/company/degron-therapeutics" alt="Degron Therapeutics on Indexed.vc" width="260" height="76" /></a>